Table 4 Interaction analysis of eGFR and prevalence of kidney adverse events in subgroups based on SU and urine pH values

1 stage CKD

0.027

 SU>480

1.88 (1.38~2.55)

1.04 (0.79~1.38)

1.04 (0.78~1.38)

reference

1.20 (0.82~1.77)

 SU ≤ 480

2.90 (1.85~4.56)

2.20 (1.48~3.26)

1.375 (0.92~2.05)

reference

1.70 (1.06~2.72)

Nephrolithiasis

0.08

 SU>480

1.73 (1.20~2.45)

0.70 (0.49~1.01)

0.93 (0.66~1.33)

reference

0.99 (0.61~1.60)

 SU ≤ 480

2.98 (1.68~5.28)

1.27 (0.73~2.20)

0.860 (0.48~1.53)

reference

1.60 (0.85~3.02)

Microhematuria

0.173

 SU>480

1.66 (1.19~2.30)

1.37 (1.00~1.89)

1.30 (0.94~1.80)

reference

1.57 (1.04~2.36)

 SU ≤ 480

2.94 (1.84~4.72)

1.47 (0.97~2.22)

1.32 (0.88~1.99)

reference

1.50 (0.95~2.39)

Proteinuria

0.234

 SU>480

2.49 (1.06~5.82)

3.91 (1.74~8.78)

3.34 (1.47~7.59)

reference

1.53 (0.53~4.44)

 SU ≤ 480

5.40 (1.53~19.08)

3.25 (0.93~11.43)

2.88 (0.82~10.20)

reference

2.12 (0.52~8.62)